Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4281286
Max Phase: Preclinical
Molecular Formula: C24H26N2O2
Molecular Weight: 374.48
Molecule Type: Small molecule
Associated Items:
ID: ALA4281286
Max Phase: Preclinical
Molecular Formula: C24H26N2O2
Molecular Weight: 374.48
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COc1ccc(OCc2cc(C)ccn2)c(-c2ccc3c(c2)CCNCC3)c1
Standard InChI: InChI=1S/C24H26N2O2/c1-17-7-12-26-21(13-17)16-28-24-6-5-22(27-2)15-23(24)20-4-3-18-8-10-25-11-9-19(18)14-20/h3-7,12-15,25H,8-11,16H2,1-2H3
Standard InChI Key: NEKARSRXGYDKMG-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 374.48 | Molecular Weight (Monoisotopic): 374.1994 | AlogP: 4.33 | #Rotatable Bonds: 5 |
Polar Surface Area: 43.38 | Molecular Species: BASE | HBA: 4 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 10.02 | CX LogP: 4.29 | CX LogD: 1.76 |
Aromatic Rings: 3 | Heavy Atoms: 28 | QED Weighted: 0.72 | Np Likeness Score: -0.59 |
1. Barker MD, Liddle J, Atkinson FL, Wilson DM, Dickson MC, Ramirez-Molina C, Lewis H, Davis RP, Somers DO, Neu M, Jones E, Watson R.. (2018) Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease., 28 (21): [PMID:30249354] [10.1016/j.bmcl.2018.09.022] |
Source(1):